Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis

This article reviews in detail the merits and unique nature of this combination lotion and also discusses a new type of strategy for treating psoriasis topically.Recent FindingsThe combination lotion proved much more efficacious than the vehicle. Moreover, when the combination lotion was compared head-to-head with each of the components alone (halobetasol, tazarotene) and vehicle lotion, the combination was clearly more efficacious after 8  weeks. In terms of safety, the combination lotion was well tolerated by the patients. The combination lotion is also unique in that it is the only superpotent topical steroid with long-term safety data of 1 year.SummaryNow that the FDA has approved a superpotent topical steroid containing a topical agent for unlimited “intermittent” use, compliance and treatment efficacy can be greatly improved. Due to this, the combination lotion can greatly enhance topical therapy for psoriasis and make maintenance therapy practical.

Source: Current Dermatology Reports - January 6, 2021 Category: Dermatology Source Type: research